Innoviva Inc. Common Stock (INVA)
Stock · NASDAQ · Health Care
$20.78as of 10/16/2026
Price chart
Active signals
INVA Signal Track Record
How signals performed across all stocks →What INVA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | +1.0% | 60% | September 17, 2026 |
| Bollinger Band Breakdown | 21 | -0.5% | 48% | September 10, 2026 |
| Bollinger Band Breakout | 20 | +0.7% | 55% | June 23, 2026 |
| 200-Day Moving Average Touch | 17 | +5.5% | 76% | July 20, 2026 |
| Any 20-session window (baseline) | -0.1% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About INVA
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIA…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 159
- Website
- www.inva.com/
Fundamentals
- 1-day range
- $20.85$21.76
- Market cap
- $1.56B
- P/E (trailing)
- 4.25
- P/E (forward)
- 9.44
- EPS (trailing)
- $4.05
- Dividend yield
- —
- Beta
- 0.38
- Avg. volume
- 777.0K
- Ex-dividend date
- September 8, 2015
- Dividend pay date
- September 30, 2015
How Innoviva Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Innoviva Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- INVAInnoviva Inc. Common Stock$20.78▼ 0.38%Market cap $1.56BP/E 4.25$16.52$25.15
- TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$34.46▼ 4.38%Market cap $1.58BP/E —$14.72$49.91
- AAPGAscentage Pharma Group International American Depository Shares$15.37▲ 4.63%Market cap $1.60BP/E —$27.12$75.1
- TYRATyra Biosciences Inc. Common Stock$18.52▼ 2.73%Market cap $1.61BP/E —$12.96$40.65
- MRVIMaravai LifeSciences Holdings Inc. Class A Common Stock$6.79▼ 3.96%Market cap $1.61BP/E —$2.55$9.42
- ANABAnaptysBio Inc. Common Stock$46.61▼ 4.31%Market cap $1.62BP/E 7.29$20.18$72.36
- HROWHarrow Inc. Common Stock$27.28▼ 5.11%Market cap $1.49BP/E —$26.96$54.85
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INVA Innoviva Inc. Common Stock | $1.56B | 4.25 | $20.78 | ▼ 0.38% | $16.52$25.15 |
| TRAX First Tracks Biotherapeutics Inc. Ordinary Shares | $1.58B | — | $34.46 | ▼ 4.38% | $14.72$49.91 |
| AAPG Ascentage Pharma Group International American Depository Shares | $1.60B | — | $15.37 | ▲ 4.63% | $27.12$75.1 |
| TYRA Tyra Biosciences Inc. Common Stock | $1.61B | — | $18.52 | ▼ 2.73% | $12.96$40.65 |
| MRVI Maravai LifeSciences Holdings Inc. Class A Common Stock | $1.61B | — | $6.79 | ▼ 3.96% | $2.55$9.42 |
| ANAB AnaptysBio Inc. Common Stock | $1.62B | 7.29 | $46.61 | ▼ 4.31% | $20.18$72.36 |
| HROW Harrow Inc. Common Stock | $1.49B | — | $27.28 | ▼ 5.11% | $26.96$54.85 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?Yahoo · 10/8/2026
- INVA vs. MRK: Which Stock Is the Better Value Option?Yahoo · 10/8/2026
- 5 Attractive Low Price-to-Sales Stocks With Promising Upside PotentialYahoo · 10/8/2026
- Should Value Investors Buy Innoviva (INVA) Stock?Yahoo · 10/8/2026
- Innoviva (NASDAQ:INVA) Fits the Affordable Growth MoldChartMill · 9/25/2026
- Oppenheimer Assumes Innoviva at Outperform, Announces Price Target of $35Benzinga · 9/23/2026
- Innoviva (NASDAQ:INVA): An Undervalued Value Stock Backed by Strong Cash FlowChartMill · 9/17/2026
Insider Activity
Insider Actions →- Marianne Zhen · August 20, 2026 · Tax Withholding1.1K @ $21
- Stephen Basso · August 20, 2026 · Tax Withholding558 @ $21
- Pavel Raifeld · August 20, 2026 · Tax Withholding1.1K @ $21
- Stephen Basso · May 20, 2026 · Tax Withholding559 @ $22.24
- Pavel Raifeld · May 20, 2026 · Tax Withholding1.1K @ $22.24
- Marianne Zhen · May 20, 2026 · Tax Withholding1.1K @ $22.24
- Josephine Linden · May 18, 2026 · Grant9.2K
- Josephine Linden · May 18, 2026 · Grant9.5K
- Josephine Linden · May 18, 2026 · Grant5.7K
- Stephen Basso · May 15, 2026 · Grant1.1K
- Pavel Raifeld · May 15, 2026 · Grant1.1K
- Marianne Zhen · May 4, 2026 · Grant31.5K
- Marianne Zhen · May 4, 2026 · Grant12.8K
- Sarah J. Schlesinger · May 4, 2026 · Grant10.0K
- Sarah J. Schlesinger · May 4, 2026 · Grant9.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 69.99M
- Total value held
- $1.61B
- Institutional holders
- 277
- Unknown11.31M
- Unknown4.44M
- Unknown4.06M
- Unknown3.14M
- Unknown3.06M
- Unknown2.28M
- Unknown2.13M
- Unknown2.02M
- Unknown1.93M
- Unknown1.91M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Innoviva (INVA) Draws Value Investor Attention Amid Low Valuation
Recent articles highlight Innoviva's low price-to-earnings ratio of 4.3, positioning it as a potential value pick compared to peers like Merck. With the stock trading near its 52-week low, analysts are debating whether the current price reflects undervaluation or persistent risk. The focus on valuation metrics suggests investors are scrutinizing the company's financial appeal rather than recent operational news.
Innoviva (INVA) Draws Value Investor Attention Amid Low Valuation. Recent articles highlight Innoviva's low price-to-earnings ratio of 4.3, positioning it as a potential value pick compared to peers like Merck. With the stock trading near its 52-week low, analysts are debating whether the current price reflects undervaluation or persistent risk. The focus on valuation metrics suggests investors are scrutinizing the company's financial appeal rather than recent operational news.